Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that, on June 22, 2023, Vistagen received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (Nasdaq) indicating that Vistagen has regained full compliance with the minimum $1.00 bid price per share or greater requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Vistagen is now in full compliance with all applicable Nasdaq listing requirements, and Nasdaq considers the matter closed.
Amazon Q4 Earnings: Revenue Beat, EPS Beat, ‘Record-Breaking’ Holiday Shopping Season And More
Amazon's fourth-quarter revenue increased 14% year-over-year to $170 billion, which beat the consensus estimate of $166.21 billion, according to Benzinga Pro. The company reported quarterly earnings of $1 per share, which beat analyst estimates of 80 cents per share.
